SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET

Thomas A Hope^{1

2

3}, Jeremie Calais^{4

5}, Ajit H Goenka⁶, Uwe Haberkorn⁷, Mark Konijnenberg⁸, Jonathan McConathy⁹, Daniela E Oprea-Lager¹⁰, Laura Trimnal³, Elcin Zan¹¹, Ken Herrmann^{12

13}, Christophe M Deroose^{14

15}

Affiliations

¹ Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.
² UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
³ Department of Radiology, San Francisco VA Medical Center, San Francisco, California.
⁴ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
⁵ Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.
⁶ Department of Radiology, Mayo Clinic, Rochester, Minnesota.
⁷ Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
⁸ Radiology and Nuclear Medicine Department, Erasmus MC, Rotterdam, Netherlands.
⁹ Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama.
¹⁰ Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
¹¹ Department of Radiology, Cleveland Clinic, Cleveland, Ohio.
¹² Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
¹³ German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany.
¹⁴ Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium; and.
¹⁵ Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.

PMID: 39572227
PMCID: PMC11705787
DOI: 10.2967/jnumed.124.269002

SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET

Thomas A Hope et al. J Nucl Med. 2025.

. 2025 Jan 3;66(1):26-33.

doi: 10.2967/jnumed.124.269002.

Authors

Affiliations

¹ Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.
² UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
³ Department of Radiology, San Francisco VA Medical Center, San Francisco, California.
⁴ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
⁵ Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.
⁶ Department of Radiology, Mayo Clinic, Rochester, Minnesota.
⁷ Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
⁸ Radiology and Nuclear Medicine Department, Erasmus MC, Rotterdam, Netherlands.
⁹ Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama.
¹⁰ Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
¹¹ Department of Radiology, Cleveland Clinic, Cleveland, Ohio.
¹² Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
¹³ German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany.
¹⁴ Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium; and.
¹⁵ Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.

PMID: 39572227
PMCID: PMC11705787
DOI: 10.2967/jnumed.124.269002

No abstract available

PubMed Disclaimer

Figures

**FIGURE 1.**
Chemical structures of FAP PET radiopharmaceuticals.

See this image and copyright information in PMC

Cited by

Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [¹⁸F]FDG in gynaecological malignancies: systematic literature review and meta-analysis.
Florit A, de Koster EJ, Sassano S, Alic L, Pisano G, van Velden FHP, Annunziata S, Primac I, Ruggiero MR, Müller C, Sala E, Fendler WP, Scambia G, de Geus-Oei LF, Fagotti A, Rufini V, Collarino A. Florit A, et al. Eur J Nucl Med Mol Imaging. 2025 Sep;52(11):3975-3989. doi: 10.1007/s00259-025-07277-0. Epub 2025 Apr 25. Eur J Nucl Med Mol Imaging. 2025. PMID: 40278857 Free PMC article.
FAPI-positron emission tomography for radiotherapy in head and neck cancer: applications and future directions.
de Ridder M, de Bree R, de Keizer B. de Ridder M, et al. Phys Imaging Radiat Oncol. 2025 Jun 5;35:100792. doi: 10.1016/j.phro.2025.100792. eCollection 2025 Jul. Phys Imaging Radiat Oncol. 2025. PMID: 40584995 Free PMC article. Review.
Recent Advances in PET and Radioligand Therapy for Lung Cancer: FDG and FAP.
Lee EJ, Chung HW, So Y, Kim IA, Kim HJ, Lee KY. Lee EJ, et al. Cancers (Basel). 2025 Aug 1;17(15):2549. doi: 10.3390/cancers17152549. Cancers (Basel). 2025. PMID: 40805245 Free PMC article. Review.
177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study.
Fu H, Huang J, Zhao L, Chen Y, Xu W, Cai J, Yu L, Pang Y, Guo W, Su B, Sun L, Wu H, Zhang J, Chen X, Chen H. Fu H, et al. Clin Cancer Res. 2025 Apr 14;31(8):1415-1426. doi: 10.1158/1078-0432.CCR-24-3918. Clin Cancer Res. 2025. PMID: 40084923 Free PMC article. Clinical Trial.
Based on small molecules: development and application of fibroblast activation protein inhibitors radiopharmaceutical in tumor precision therapy.
Luo Y, Fu H, Yu C. Luo Y, et al. Front Pharmacol. 2025 May 14;16:1593380. doi: 10.3389/fphar.2025.1593380. eCollection 2025. Front Pharmacol. 2025. PMID: 40438601 Free PMC article. Review.

See all "Cited by" articles

References

1. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274:36505–36512. - PubMed
1. Juillerat-Jeanneret L, Tafelmeyer P, Golshayan D. Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase? Expert Opin Ther Targets. 2017;21:977–991. - PubMed
1. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–598. - PubMed
1. Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99–115. - PubMed
1. Kratochwil C, Flechsig P, Lindner T, et al. . 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–805. - PMC - PubMed

Grants and funding

LinkOut - more resources

Full Text Sources
- HighWire
- PubMed Central
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET

Affiliations

SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET

Authors

Affiliations

Figures

Similar articles

Cited by

References

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous